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Abstract 
Malaria is an infectious disease caused by parasites of the genus Plasmodium that 
inflicts approximately one million deaths per annum worldwide. Chemical validation 
of new antimalarial targets is urgently required in view of rising resistance to current 
drugs. One such putative target is the enzyme N-myristoyltransferase (NMT), which 
catalyzes N-myristoylation of protein substrates. Here we report an integrated 
chemical biology approach to explore protein myristoylation in the major human 
parasite P. falciparum, combining chemical proteomic tools for identification of the 
myristoylated and glycosylphosphatidylinositol-anchored proteome with selective 
small molecule NMT inhibitors. We demonstrate that NMT is an essential and 
chemically tractable target in malaria parasites both in vitro and in vivo, and show 
that selective inhibition of N-myristoylation leads to catastrophic and irreversible 
failure to assemble the inner membrane complex, a critical subcellular organelle in 
the parasite life cycle. Our studies provide the basis for development of new 
antimalarials targeting NMT. 
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Malaria is an infectious disease caused by parasites of the genus Plasmodium, and 
is among the most serious in the developing world, resulting in an estimated 200 
million cases and 1.2 million deaths in 20101. The majority of cases and mortality are 
due to P. falciparum in sub-Saharan Africa, whilst P. vivax is widespread and causes 
persistent infections2. Resistance has been recorded against all frontline therapies, 
and the need for new drugs is widely recognized3. N-Myristoyltransferase (NMT, EC 
2.3.1.97) catalyzes transfer of the lipid myristate (C14:0) from myristoyl coenzyme A 
(Myr-CoA) to specific substrate proteins in eukaryotes4, and has been explored pre-
clinically as a target in fungal5 and trypanosome infections6, and suggested as a 
potential target in malaria and leishmaniasis7. Protein N-myristoylation occurs 
predominantly co-translationally at an N-terminal glycine following removal of initiator 
methionine (Fig. 1a); although an N-terminal glycine is essential, there is no pan-
species consensus sequence for myristoylation4.  In silico analyses suggest that up 
to 2% of proteins in P. falciparum may be substrates for NMT (Supplementary 
Table S1), although lack of suitable training sets for Plasmodium myristoylation 
results in inconsistent predictions8. To date, only two proteins have been shown to 
be N-myristoylated in their native context in P. falciparum – calcium-dependent 
protein kinase-1 (CDPK1)9 and glideosome-associated protein 45kDa (GAP45)10 – 
and there is indirect evidence for a small number of other substrates10, 11, 12, 13.  N-
Myristoylation regulates membrane localization and protein complex assembly in 
eukaryotes14, and selective inhibition of NMT is hypothesized to lead to pleiotropic 
effects on the parasite through multiple downstream substrates. Plasmodium species 
possess a single NMT gene15 and partial knockdown of NMT expression in the 
rodent malaria parasite P. berghei was found to result in rapid depletion of 
parasitemia in vivo, demonstrating that NMT is essential in this murine model of 
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malaria16. However, target validation in human malarial parasites is particularly 
challenging due to their complex life cycle, the limited range of genetic tools 
available, and the very low efficiency of genetic modification17. Despite intensive 
research efforts, conditional genetic knockout of an essential gene in P. falciparum 
has not been demonstrated to date, and thus chemical genetic knockdown 
approaches based on small molecule inhibitors are a particularly powerful and 
versatile strategy for target validation. 
Here we present an integrated chemical biology approach to understand inhibition of 
N-myristoylation in P. falciparum parasites that enables both the study of protein 
myristoylation and the chemical dissection of NMT as a drug target in this genetically 
intractable organism. These studies greatly expand knowledge of both N-
myristoylated and glycosylphosphatidylinositol (GPI) anchored proteins in 
Plasmodium, and provide the first compelling evidence that NMT is a druggable 
target in the symptomatic blood stage of the most important human malaria parasite. 
Using these tools in combination with quantitative whole proteome analyses and 
cellular studies, we demonstrate that NMT inhibition results in a catastrophic and 
irreversible failure to form critical parasite subcellular structures, followed by rapid 
parasite cell death. Furthermore, we define potent starting points for the 
development of NMT inhibitors as potential antimalarials that are active against 
human malaria parasites in vitro, and in vivo in an animal model of malaria. 
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Results 
Myristoyl-CoA analogue YnMyr-CoA is a biomimetic substrate for Plasmodium 
NMT 
Lipid probes bearing a bioorthogonal tag such as a terminal alkyne are powerful 
tools for analysis of protein lipidation in living systems18, 19. The myristate surrogate 
tetradec-13-ynoic acid (YnMyr) can be transferred from YnMyr-CoA thioester to 
target proteins by recombinant NMT20, in bacterial co-expression systems21 or in 
mammalian cells22. Subsequent chemoselective ligation through copper(I)-catalyzed 
[3+2] azide-alkyne cycloaddition (CuAAC) imparts a range of useful functionality to 
tagged proteins, including a fluorophore and/or affinity label (Fig. 1b)20, 22, 23, 24. We 
determined the structure of NMT from P. vivax (PvNMT, which shares >80% identity 
with P. falciparum NMT (PfNMT))25 in complex with YnMyr-CoA (PDB 2YNC; 
Supplementary Fig. S1 and Table S2), revealing that YnMyr-CoA occupies an 
extended groove that runs across one face of the enzyme, with the YnMyr chain 
occupying the fatty acyl binding pocket (Fig. 1c). The terminal sp hybridized carbon 
atoms are accommodated without steric clashes and the hydrophobic contacts and 
native interactions of the thioester carbonyl with backbone amide and polar side 
chain moieties are preserved (Fig. 1c)26. This structure is the first reported example 
of a tagged analogue of a post-translational modification precursor in complex with 
its cognate transferase, and together with kinetic data (Supplementary Fig. S2) 
indicates that a terminal alkyne moiety is fully compatible with enzymatic transfer of 
YnMyr to substrate proteins.  
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YnMyr tags N-myristoylated and GPI-anchored proteins in P. falciparum blood 
stage parasites 
We next investigated the capacity of YnMyr to tag proteins in the asexual stage of 
the parasite, which invades and replicates within red blood cells (RBCs). Intracellular 
P. falciparum 3D7 parasites (schizonts) were treated with YnMyr at concentrations 
up to 50 µM and allowed to develop over 5 h; no changes were observed in 
morphology or life cycle progression in YnMyr-treated parasites. Parasite proteins 
were isolated and CuAAC ligation to tri-functional capture reagent AzTB (azido-
TAMRA-PEG-Biotin; Supplementary Fig. S3)27 enabled direct in-gel fluorescence 
detection of protein tagging following SDS PAGE (Fig. 2a). YnMyr tagging was 
concentration-dependent with no detectable background, readily out-competed by 
excess myristate, and inhibited by the protein synthesis inhibitor cycloheximide 
(CHX, Supplementary Fig. S4), consistent with biomimetic co-translational 
modification of target proteins. The biotin label in AzTB further permitted quantitative 
immobilization of fluorescently labeled proteins on streptavidin-coated beads 
(Supplementary Fig. S5). The known N-myristoylated proteins CDPK1 and 
GAP4510, 28 were selectively pulled down from parasites cultured in the presence of 
YnMyr, and resistance of labeling to base and hydroxylamine indicated the presence 
of N-acyl (amide linked) YnMyr (Fig. 2a and Supplementary Fig. S6). Control 
experiments cross-comparing metabolic incorporation of the longer chain palmitate 
probe YnPal (heptadec-14-ynoic acid) confirmed that YnMyr was not significantly 
incorporated into sites of S-palmitoylation, which occurs through a thioester linked to 
cysteine side chains (Supplementary Fig. S7). However, a substantial fraction of 
the fluorescently labeled bands were base sensitive suggesting the presence of 
ester-linked YnMyr (Fig. 2a). Ester-linked incorporation of myristate at the GPI 
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anchor inositol is characteristic of Plasmodium species29, and we found that the 
abundant GPI-anchored surface protein MSP1 was indeed tagged by YnMyr in a 
base-sensitive manner (Fig. 2a). Taken together, these data suggest that YnMyr is a 
high-fidelity myristate mimetic in live parasites, and can be used as a probe for both 
N-myristoylated and GPI-anchored proteins under standard culture conditions. 
Chemical proteomic profiling of N-myristoylated and GPI-anchored proteins in 
P. falciparum  
We next performed de novo identification of YnMyr targets in P. falciparum by LC-
MS/MS based chemical proteomics after AzTB ligation, pull-down and protein digest, 
using both gel-based and gel-free approaches. Tryptic peptides were analyzed by a 
standard proteomics workflow, and proteins found with very high (>99 %) confidence 
and >4-fold enrichment compared to controls were considered for further analysis; 
proteomic methods are described in detail in Supplementary Methods. N-
Myristoylated target proteins were mapped to specific regions of the gel following 
gel-based proteomics (Fig. 2b; Supplementary Fig. S8 and Table S6), identifying 
ADP-ribosylation factor 1 (ARF1) as the major component of the strongest 
fluorescent band.  A novel antibody directed against PfARF1 further confirmed this 
assignment (Fig. 2c). Base-treatment prior to pull-down was used to dissect the 
contributions of GPI-anchored and N-myristoylated proteins; identification of MSP1 
and predicted GPI-anchored proteins was dramatically reduced or eliminated by 
base treatment, whilst putative N-myristoylated proteins were unaffected (Fig. 3a; 
Supplementary Tables S3, S4 and S5)30, 31. YnMyr-tagged peptides were not 
detected in these analyses, due to the presence of the biotin label added during 
CuAAC ligation that anchors the peptide to the resin during tryptic digest. Indeed, 
direct determination of the site of modification has been recognized as a significant 
8 
 
unsolved challenge in metabolic tagging of lipidated proteins32 due to poor release of 
the biotinylated peptide from the streptavidin resin and the large size of the resultant 
label. We therefore designed a new tetra-functional capture reagent (AzKTB, Fig. 
3b) which bears a short trypsin-cleavable peptide sequence between the azide 
module and the TAMRA/PEG-biotin labels. Tryptic on-bead digest releases the 
YnMyr-modified peptide bearing a hydrophilic zwitterionic moiety, permitting the site 
of YnMyr modification to be determined unambiguously by tandem MS 
(Supplementary Fig. S9). Using this new approach, 17 N-terminal YnMyr-Gly motifs 
were detected (Fig. 3a and Supplementary Table S7), further confirming the fidelity 
of the YnMyr probe for NMT substrates in live parasites.  
Taken together, these data provide direct experimental evidence for more than 30 
NMT substrates in wild type parasites, encompassing a diverse range of functions 
including motility, protein transport, parasite development and phosphorylation 
pathways (Fig. 3c). As expected, many substrates have predicted or known 
localization at membranes or in membrane-bound compartments (Supplementary 
Fig. S10). Across the proteomic datasets five proteins had previously been 
annotated as PfNMT substrates via direct (GAP45, CDPK1) or indirect (GRASP113, 
Armadillo repeats-only protein ARO33, ARF130) experimental evidence. New proteins 
were identified that are N-myristoylated in other eukaryotes, including several 
ARF/ARL proteins and the 26S proteasome regulatory subunit 4 (P26s4), which is 
highly enriched in YnMyr-tagged samples34. Interestingly, studies in yeast have 
shown that loss of N-myristoylation of the yeast P26s4 homologue results in aberrant 
localization of the entire proteasome complex34 and the proteasome has recently 
been described as a promising drug target in P. falciparum35. Other substrates with 
important functions include Protein Kinase A regulatory subunit PKAr36, the small 
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GTPase Rab5b37 and CDPK4, a kinase essential in gametogenesis and disease 
transmission38. We also identified the small inner-membrane complex (IMC) proteins 
ISP1 and ISP3; along with GAP45 these proteins have important roles in regulating 
formation of the IMC, a subcellular organelle that is critical for assembling the 
molecular motor apparatus required for RBC invasion39.  
Identification and structural characterization of potent small molecule 
inhibitors of P. falciparum and P. vivax NMTs 
The diversity of function of the identified N-myristoylated proteome in P. falciparum 
indicates that specific NMT inhibition could substantially reduce parasite viability. To 
support this hypothesis, we sought to identify potent chemical inhibitors to enable 
selective and tunable chemical genetic knockdown of NMT activity in live parasites. 
As noted above, such tools are particularly powerful when applied to P. falciparum 
since there is currently no proven genetic method for inducible knockdown of an 
essential gene in this parasite. Through further development of our recently-reported 
Plasmodium NMT inhibitors40 combined with screening known inhibitors of NMT from 
other organisms we identified two distinct PfNMT/PvNMT inhibitor series 1 and 2 
(Fig. 4a). Series 1 compounds were first reported as inhibitors of T. brucei NMT, and 
compound 1a is effective on trypanosomes in vitro and in vivo6; however, the 
causative agents of malaria and trypanosomiasis have entirely different mechanisms 
of infection and disease pathology. Series 2 is derived from a P. falciparum NMT 
inhibitor based on a benzothiophene scaffold,40 the structure-guided development of 
which will be reported elsewhere in due course. X-ray crystallography was used to 
determine the binding mode of the most potent compounds 1a and 2a in ternary 
complexes with PvNMT and a non-hydrolyzable myristoyl-CoA analogue (PDB 
2YND and 2YNE; Supplementary Table S2). Both inhibitors bind at the peptide 
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binding pocket, with 1a exhibiting a similar binding mode to that observed in NMTs 
from other species (Fig. 4b and Supplementary Fig. S11). A salt bridge is formed 
between the positively charged piperazine (1a) or piperidine (2a) nitrogen and the C-
terminal carboxylate of the enzyme, which plays an essential catalytic role during 
myristate transfer4. Despite this common point of contact, the trajectory of these two 
chemotypes through the binding site is distinct. Substitution of the trimethyl pyrazole 
(1c, 2b) substantially reduces potency, likely due to reduced H-bonding capacity, 
whilst sulfonamide alkylation in 1b yielded a more subtle decrease (Fig. 4a). 
Although 1a-c41 are more potent against Homo sapiens NMT (HsNMT1) than against 
the Plasmodium enzymes, RBCs lack de novo protein synthesis and do not express 
NMT, suggesting that in vitro culture would not be compromised42. In contrast, 2a-b 
possess promising selectivity over HsNMT1, with 2a being the most potent PfNMT 
and PvNMT inhibitor reported to date.  
NMT inhibitors act on-target to kill P. falciparum blood stage parasites and 
reduce parasite burden in an in vivo model of malaria 
With inhibitor and substrate chemical probes for PfNMT characterized at the 
structural, biochemical and proteomic level, we sought to determine whether 1a-c 
and 2a-b act on-target in parasites in culture and to assess NMT as a potential drug 
target in blood stage P. falciparum. Analysis of EC50 values for parasite growth 
inhibition in synchronized intraerythrocytic P. falciparum cultures revealed that 
translation of potency from enzyme to cell (EC50/Ki(app)) varied significantly across 
series (Fig. 5a). Uninfected RBCs remained morphologically normal 
(Supplementary Fig. S12). Since protein N-myristoylation occurs co-translationally 
we reasoned that inhibition of NMT in parasites could be assessed directly by 
treatment with inhibitor combined with pulse tagging with YnMyr. When tagging 
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experiments were repeated in the presence of 1a a highly specific dose-dependent 
depletion of fluorescence was observed for all bands previously identified as NMT 
substrates, with no change in GPI-anchored proteins (Fig. 5b; Supplementary Figs. 
S13 and S14). Parallel experiments with the tagged methionine surrogate 
azidohomoalanine (AHA43, Supplementary Fig. S3) showed that 1a does not 
directly affect protein synthesis (Supplementary Fig. S15). Selective inhibition was 
further confirmed for specific substrate proteins by Western blot against CDPK1 and 
GAP45, and using novel antibodies directed against ARF1 and ARO (Fig. 5b; 
Supplementary Figs. S16 and S17). Total abundance of each protein analyzed was 
unaltered by inhibitor treatment over this short pulse tagging period; however, on 
pull-down the amount of each YnMyr-tagged substrate recovered was dose-
dependently inhibited, whilst MSP1 remained unaffected. Quantification of the 20 
kDa ARF1 band by fluorescence intensity or Western blot gave 346 nM as the 
inhibitor concentration required for 50% reduction in YnMyr tagging (here termed 
TC50) for 1a, closely matching the TC50 values calculated for other specific substrates 
by quantification of Western blots (Fig. 5c and Supplementary Fig. S18).  
Series 1 and 2 were compared for their capacity to knock down NMT activity in 
parasites with the aim of rationalizing their diverse enzyme to cell translation (Fig. 5a 
and Supplementary Figs. S19 and S20). An excellent correlation was observed 
between TC50 and parasite viability (EC50) across all compounds tested (R2 = 0.97, 
Fig. 5a), establishing a direct link between in-cell NMT inhibition and efficacy, and 
resolving the differences in translation between members of series 1 and 2. In 
particular, compounds 1a and 2a have very similar effects on protein myristoylation 
in the cell despite their significantly different Ki values, resulting in similar EC50 
values for parasite killing (Fig. 5a). These data demonstrate that 1a-c and 2a-b 
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possess the same on-target mode of action, and establish the chemical tractability of 
NMT in blood stage human malaria parasites.  
We also examined the impact of NMT inhibition on parasite burden in vivo in the 
rodent malaria parasite P. berghei. Both 1a and 2a maintained reasonable potency 
against recombinant PbNMT (Ki = 90 and 14 nM, respectively), but initial 
experiments found that 1a induced toxicity in vivo at sub-therapeutic concentrations. 
However, when 2a was administered to infected mice a significant (p  0.01, n = 3) 
reduction in parasitemia was observed compared to controls (PBS vehicle) over the 
course of 3 days treatment (50 mg/kg intraperitoneally, twice daily) (Fig. 5d). 
Furthermore, 2a caused no acute toxicity and animals survived without visible 
symptoms past day 3, whereas all control mice needed to be euthanized due to 
acute symptoms of malaria. This first demonstration of in vivo activity of a chemical 
inhibitor of Plasmodium NMT is encouraging, particularly given that the potency and 
pharmacokinetic properties of 2a are suboptimal (Supplementary Table S8). 
NMT inhibition results in formation of non-viable parasites lacking critical 
components required for development and RBC invasion 
Having confirmed on-target action of NMT inhibitors in parasites, we sought to use 
these tools to investigate how NMT inhibition leads to parasite cell death. During 
asexual reproduction, P. falciparum undergoes a 45-48 hour life cycle within infected 
RBCs (iRBCs), maturing from ring stage, to trophozoite, and then schizont, before 
differentiation into merozoites that egress and reinvade RBCs (Fig. 6a). We 
examined the effects of NMT inhibition on life stage progression, monitoring growth 
at 1 µM 1a, a dose that causes approximately 80% inhibition of protein myristoylation 
in parasites (Fig. 5). NMT inhibitor or DMSO vehicle (control) was added to highly 
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synchronized ring stage parasites 2 hours post-invasion (PI), and the parasite 
population was monitored up to 45 hours PI. Whilst control parasites progressed as 
expected over 45 hours to form multinucleate schizonts, 1a-treated parasites 
became trapped in a morphologically distinct life stage (here termed a 
‘pseudoschizont’). Nuclear staining (DAPI) revealed that at 45 hours all (n = 50, p < 
10-30) multinucleate parasites contained 4-7 (5.6 ± 1.1) nuclei in the presence of 1a, 
compared to ca. 20 (19.6 ± 2.7) nuclei in control schizonts (Fig. 6a and 
Supplementary Fig. S21). The clarity and severity of this phenotype is striking given 
that 1a was applied at a concentration that does not completely eliminate NMT 
activity in cells, and is consistent with the observed high sensitivity of parasites 
towards NMT inhibition (Fig. 5). At 66 hours PI, DMSO-treated parasites had 
egressed and reinvaded RBCs as expected, developing into new ring stages and 
resulting in an increase in parasitemia. However, in the presence of 1a parasitemia 
dropped by >85%, showing that NMT inhibition results in a substantial loss of 
parasite viability (Supplementary Fig. S22). 
In order to characterize the distinguishing features of pseudoschizonts, we 
performed a quantitative proteomic analysis in pseudoschizonts (inhibitor-treated) 
and schizonts (control) at 45 hours PI. The relative abundance of 1181 parasite 
proteins was determined through label-free quantification, revealing a conspicuous 
clustering amongst strongly affected proteins with known function (Fig. 6b and 
Supplementary Table S9). Multiple markers of the Inner Membrane Complex (IMC) 
were greatly reduced in abundance in inhibited cells (e.g. MyoA, MTIP, GAP45, 
ISP3), as were a set of late-expressed proteins specific to apical (secretory) 
organelles in developing merozoites; these included ARO, PTRAMP and key RBC 
binding proteins and antigens (e.g. EBA140/175/181, RH2a). Western blot analyses 
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of GAP45, MTIP, CDPK1 and ARO further confirmed marked depletion of these 
proteins in pseudoschizonts (Fig. 6c). Interestingly, there was relative accumulation 
of a set of soluble secreted proteins, including several members of the serine repeat 
antigen family (SERA) which under normal conditions are exported and processed 
during schizont development. 
The IMC is comprised of flattened membrane compartments lying directly under the 
plasma membrane, where one of its roles is assembly of the molecular motor 
complex (including MTIP, MyoA and GAP45) that drives invasion of RBCs. In the 
intracellular parasite, assembly of the IMC occurs during schizogony and can be 
visualised with protein markers such as GAP4544. In Plasmodium nuclear division 
precedes cell division, and the IMC initially appears as small ring-like structures, 
which then extend around developing merozoites during schizont segmentation (cell 
division). This transition was recapitulated in immunofluorescence images of DMSO-
treated parasites at 35 and 45 hours PI, whereas in the inhibitor treated parasites the 
IMC structure was not visible at either time point (Fig. 6d). Given the established 
importance of the IMC in parasite development and invasion, we hypothesized that 
NMT inhibition-induced loss of the IMC would have catastrophic and irreversible 
consequences for parasite viability. Indeed, when inhibited parasites (1 µM 1a) were 
analyzed 10 hours later (at 55 hours PI), iRBCs bearing pseudoschizonts were 
largely eliminated even when inhibitor was removed at 45 hours PI, whereas control 
parasites egressed and reinvaded new RBCs to form new ring stages over the same 
timeframe (Fig. 6e).  
Discussion 
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Here we have established a novel chemical approach to study N-myristoylation and 
inhibition of NMT in the most important human malarial parasite, and demonstrated 
that NMT is an essential and chemically tractable target in P. falciparum. Metabolic 
chemical tagging has enabled the first proteome-wide survey of both N-myristoylated 
and GPI-anchored proteins in P. falciparum. Previously, identification of PfNMT 
substrates relied on painstaking generation of mutant parasites or specific antibodies 
and radiolabeling that are impractical for high-throughput studies. In contrast, our 
chemical approach identifies substrates directly across the proteome in their natural 
context in live parasites, without the need for genetic manipulation and substrate 
overexpression. In combination with a new reagent for the identification of protein 
lipidation sites by metabolic tagging, this technology provides high confidence 
assignment of over 30 NMT substrates; the majority are identified for the first time in 
this study, and have roles in a wide range of essential processes. These include 
protein trafficking and secretion (ARF1, Rab5b, ARO), ion channel regulation (PKAr), 
organelle biogenesis (GRASP1), motility (CDPK1, GAP45), inner membrane 
complex (IMC) integrity (ISP1, ISP3, GAP45), development (CDPK4), and protein 
homeostasis (P26s4). Combining PfNMT inhibitors with a chemical proteomic 
toolbox (YnMyr, AHA, AzKTB) backed up by extensive characterization (biochemical, 
structural, in vitro, in vivo) provides a powerful and self-consistent validation of on-
target specificity. This study is also the first to apply AHA to track de novo protein 
synthesis in Plasmodium; notably, metabolic tagging proceeds efficiently without the 
need for defined media, and we anticipate that AHA will be a powerful alternative to 
radiolabeling for monitoring protein synthesis in malaria parasites.  
Whilst work on fungi and trypanosomes suggests NMT may be an interesting 
potential target in infectious disease, Plasmodium parasites are evolutionarily 
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specialized, and infect their host and mosquito vector through unique and highly 
complex mechanisms; the specific consequences of PfNMT inhibition were thus 
unknown prior to the work reported here. Our chemical approach offers a unique 
opportunity to examine the phenotype arising from perturbation of the pathways in 
which NMT substrates are involved, particularly since knockout of an essential gene 
such as PfNMT is currently intractable in human malaria parasites. In particular, we 
discovered that PfNMT inhibition induced an unexpected, irreversible and 
catastrophic failure to assemble the IMC during early schizogony in asexual blood 
stage parasites. This was accompanied by loss of essential components of the 
myosin motor that drives RBC invasion (MTIP, MyoA), as well as the absence of 
proteins critical for parasite engagement of new RBCs (EBA140/175/181, RH2a). A 
strong reduction in proteins synthesized late in intracellular development, including 
characteristic markers of organelles assembled at the apical end of developing 
merozoites (rhoptries/ARO, micronemes/EBA family), provides strong evidence that 
inhibited parasites are non-infectious33. Marked retention and failed processing of 
key proteins exported during late schizogony (SERA family, GBP, MSP9) further 
illustrates a failure to progress to merozoites. Interestingly, parasites commit to early 
rounds of nuclear division but are unable to proceed through cell division, supporting 
recent evidence for a key role of the IMC in development in addition to invasion44.  
GAP45, ISP1 and ISP3 are NMT substrates identified here that are candidates for 
driving this IMC-related phenotype. N-Myristoylated GAP45 acts as a scaffold that 
spans the space between the plasma membrane and the IMC45; it also has an 
essential role in organizing the acto-myosin motor that drives invasion of RBCs44. 
We recently demonstrated that P. berghei ISP1 and ISP3 are highly expressed in 
invasive stages, and localize to the anterior apical end of the parasite where IMC 
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organization is initiated39. Whilst deletion of ISP3 in P. berghei is compensated by 
up-regulation of ISP1, NMT inhibition may result in simultaneous inactivation of both 
proteins through loss of the membrane anchor. Loss of the IMC is sufficient to 
explain the irreversible and cidal mode of action of PfNMT inhibition during early 
schizogony, and failure to develop into infective merozoites. However, the 
comparative whole-proteome dataset obtained here shows that this is far from the 
only phenotype arising from PfNMT inhibition, and provides a rich resource that can 
be mined to initiate future studies of IMC formation, protein trafficking and assembly 
of the invasion apparatus. 
Chemical knockdown of PfNMT effectively combines the benefits of a selective 
enzyme inhibitor with a defined multi-target, pleiotropic downstream mode of action. 
We have shown here that P. falciparum is highly sensitive to a global drop in N-
myristoylation, and structural characterization of the binding modes of inhibitors at 
the protein substrate binding pocket of Plasmodium NMT provides the potential for 
future improvements in potency and selectivity through structure-guided design. 
Remarkably, despite unoptimized pharmacokinetic (PK) properties and modest in 
vitro potency, NMT inhibitor 2a significantly reduced parasitemia in the rodent model 
P. berghei with no acute toxicity, providing further evidence for the druggability of 
NMT in malaria. This in vivo proof of principle suggests that compounds with 
improved potency and PK properties could form the basis for an antimalarial drug 
discovery program46. 
In future studies, the chemical tools described here may be applied to examine the 
role and druggability of PfNMT and N-myristoylation in other stages of the parasite, 
including in the sexual blood stages and liver stages that are important targets for 
blocking transmission. Our data suggest that NMT inhibitors could be highly effective 
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against these life stages; for example CDPK4, identified here as an NMT substrate, 
is a promising target for kinase inhibitors that block development of sexual stage 
parasites38, whilst invasion of liver cells requires an intact IMC47. The chemical tools 
described here also provide a novel approach to study the role of the IMC in parasite 
development, given the striking effects of NMT inhibition on this structure. Future 
studies could usefully focus on proteins lacking functional annotation that are 
strongly changed in abundance in pseudoschizonts. Finally, contribution to parasite 
cell death could be explored for substrates identified here that have no annotated 
function, and our chemical tools will facilitate discovery of novel biology underlying 
these proteins.  
Taken together, our results provide new insights into the scope and role of protein N-
myristoylation in Plasmodium, and show for the first time that NMT is a chemically 
tractable target in the symptomatic stage of the most important human malarial 
parasite.  
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Methods 
This section contains key experiments only. An extended experimental section is 
provided in the Supplementary Methods. Procedures used in this study were 
approved by the United Kingdom Home Office and carried out in compliance with 
European Directive 86/609/EEC for the protection of animals used for experimental 
purposes and in accordance with the United Kingdom “Animals (Scientific 
Procedures) Act 1986”. 
Chemical probes 
Synthesis of YnMyr, YnPal, AzTB and YnTB has been described previously20, 27. 
AHA was purchased from Iris Biotech. Synthesis of other compounds is described in 
the Supplementary Methods. 
Parasite culture 
Parasites were cultured as described previously and schizont stages purified using 
magnetic columns (MACS),48 before returning to culture for 2-4 h and synchronizing 
the newly invaded ring-stage parasites with 5 % D-sorbitol,49 one cycle prior to use.  
YnMyr tagging and labeling 
For tagging, assays were set up using parasites at 40 h post invasion (based on 
initial Giemsa-stained smear observations) and diluted to ~10 % parasitemia. A 
haematocrit of 4 % was used to increase the total number of parasites harvested. To 
each culture the required volume of YnMyr, YnPal, AHA or CHX was added from 
stocks, along with any inhibitors. DMSO controls were set up in parallel. Cultures 
were re-incubated (37 °C) for a further 5 h. Parasite cultures were pelleted and the 
red cells lysed in 1 × culture volume of 0.15 % saponin in PBS. Pellets were washed 
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twice in the same buffer to remove red cell proteins. Parasite proteins were extracted 
using 1 % Triton X-100 in 10 mM Na2PO4 pH 8.2 with protease inhibitors (EDTA-
free, Roche) and incubated overnight at 4 °C with rotation. Extracts were pelleted 
and the concentration of protein in the supernatant determined by DC protein assay 
(Bio-Rad). 
CuAAC bioorthogonal ligation and pull-down of labeled proteins was carried out 
essentially as previously described21; full details are given in Supplementary 
Methods, along with details of in-gel fluorescence imaging and immunoblot analysis. 
Proteomic identification of YnMyr tagged proteins by LC-MS/MS 
Following CuAAC ligation and pull-down, samples were reduced, alkylated and 
digested on-bead with trypsin, as described in the Supplementary Methods. LC-
MS/MS was carried out using an RSLCnano HPLC system (Dionex, UK) and an 
LTQ-Orbitrap-Velos mass spectrometer (Thermo Scientific). Data were further 
processed using Mascot (version 2.2.04, Matrix Science Ltd.) and Scaffold (version 
3.6.02, Proteome Software). Protein identifications were required to contain at least 
2 peptides exceeding 95 % probability giving a calculated protein false discovery rate 
of 0.0 %. Further experimental details and a description of data analysis are given in 
the Supplementary Methods. 
Proteomics analysis of inhibited parasites 
Equal protein quantities in whole cell lysate of parasites (45 h PI) cultured in 
presence of NMT inhibitor (1 µM 1a) or DMSO vehicle were processed by FASP™,50 
subjected to tryptic digest and analyzed by nanoLC-MS/MS (n = 4). Protein 
identification (>99% confidence) and label-free quantification in MaxQuant produced 
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a list of 1900 parasite proteins; data were filtered in Perseus v1.4.1.3 for 
completeness (minimum 3 quantifications per protein per group) yielding 1181 
proteins for which relative abundance was determined using a two-tailed t-test (FDR 
= 0.05, 250 randomizations). 
Supplementary Methods 
Synthesis and characterization of compounds, protein crystallography, parasite 
assays, in vivo experiments, pharmacokinetics analysis, immunofluorescence and 
immunoblot analysis and further details of CuAAC labeling, gel analysis and LC-
MS/MS proteomics is described in the Supplementary Methods. Substrate kinetic 
and inhibition assays for NMT were carried out essentially as described previously;25, 
51
 details are given in the Supplementary Methods. 
Accession codes 
Primary accessions (Protein Data Bank): 2YNC (PvNMT-YnMyrCoA); 2YND 
(PvNMT-NHMCoA-1a); 2YNE (PvNMT-NHMCoA-2a). 
Referenced accessions (Protein Data Bank): 1IID (ScNMT-NHM-GLYASKLA), 4A95 
(PvNMT-NHM), 2WUU (LdNMT-NHM), 2P6E (ScNMT-MyrCoA), 2WSA (LmNMT-
MyrCoA-1a), 3IWE (HsNMT1-MyrCoA-1a). 
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Figure legends 
Figure 1: YnMyr-CoA is an effective substrate mimic for P. falciparum and P. 
vivax N-myristoyltransferases. (a) Co-translational N-myristoylation by NMT and 
Myr-CoA at an N-terminal glycine. (b) YnMyr tag & label strategy: YnMyr is fed to 
parasites in culture and transferred to substrate proteins by metabolic incorporation. 
Proteins are isolated and ligated by copper (I) catalyzed azide-alkyne cycloaddition 
(CuAAC) to a multifunctional capture reagent, followed by enrichment and 
downstream analysis. The cleavable linker is an optional module in the capture 
reagent that enables direct identification of the modification site by MS/MS. (c) The 
structure of YnMyr-CoA in PvNMT was determined by X-ray crystallography to 
1.75 Å resolution (PDB 2YNC). At left: overall structure of PvNMT showing YnMyr-
CoA (cyan), with a peptide substrate (PDB 1IID) modeled in (green) following least-
squares superposition of the respective protein backbone atoms in PyMOL (DeLano 
Scientific). At right: key interactions made by YnMyr-CoA in the PvNMT acyl-CoA 
binding site, showing accommodation of the YnMyr chain in the hydrophobic acyl 
binding pocket and interactions of the thioester carbonyl. 
Figure 2: YnMyr tags N-myristoylated and GPI-anchored proteins in blood 
stage P. falciparum. (a) YnMyr was fed to parasites in culture, ligated by CuAAC to 
AzTB and a portion subjected to base (0.2 M NaOH) or hydroxylamine (1 M NH2OH) 
treatment to differentiate amide and ester-linked YnMyr. Samples were analyzed by 
in-gel fluorescence (top) or enriched by pull-down on streptavidin beads and 
analyzed by Western blot (WB; bottom). MSP1 is detected as the processed ~45 
kDa GPI-anchored C-terminal fragment. (b) Summary of N-terminal glycine-
containing proteins found by gel-based proteomics following base treatment and pull-
down on streptavidin beads. Proteins are grouped by the gel slice in which they were 
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predominantly found and dominant proteins in each slice are highlighted in bold. (c) 
Confirmation of the major fluorescent band as ARF1 by Western blot against a novel 
anti-ARF1 antibody, analyzed before and after pull-down on streptavidin beads; a 
shift to higher molecular weight following addition of AzTB is observed only for 
tagged ARF1 (marked by arrow), which precisely overlays with the fluorescent band 
both before and after pull-down.  
Figure 3: Chemical proteomic discovery and direct detection of modification 
site for N-myristoylated and GPI-anchored proteins in blood stage P. 
falciparum. (a) Assigned spectra profile (vertical log scale) of proteins identified 
from a representative gel-free analysis +/- base-treatment of samples, showing those 
proteins predicted or known to be GPI-anchored (blue bars), those containing an N-
terminal glycine indicative of N-myristoylation (red bars), and those for which N-
terminal YnMyr was detected directly by MS/MS (following ligation to AzKTB); other 
proteins are shown in white. (b) Structure of capture reagent AzKTB. (c) Functional 
annotation of 31 potential NMT substrates: all substrate proteins carry a base-
insensitive modification, an N-terminal glycine, and evidence of N-terminal YnMyr 
and/or bioinformatic prediction of N-myristoylation. 
Figure 4: Compounds 1a-c and 2a-b bind in the Plasmodium NMT peptide 
binding pocket and inhibit the recombinant enzyme. (a) Structures and Ki(app) 
(apparent inhibitor dissociation constant) against recombinant PfNMT and PvNMT, 
and the host enzyme HsNMT1, for series 1a-c and 2a-b; IC50 values were 
determined by a fluorogenic assay51 and differences in substrate Km accounted for 
using the Cheng-Prusoff equation to give a value for apparent Ki. Errors are quoted ± 
standard error (n  3). (b) Structures for 1a and 2a in PvNMT were determined by X-
ray crystallography with a non-hydrolyzable myristoyl-CoA (NHM) cofactor to 1.89 or 
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1.72 Å resolution (PDB 2YND and 2YNE), respectively. Left: interactions made by 2a 
(green) in the peptide binding site showing a water-mediated hydrogen bond to 
Ser319, an ionic bond to the C-terminal acid (Leu410) and interactions with aromatic 
residues Tyr334 and Tyr211. NHM is shown in cyan. Right: overlay of binding mode 
of 1a (yellow) and 2a (green) in PvNMT, following alignment of the protein backbone 
in PyMOL (DeLano Scientific). 
Figure 5: Inhibition of NMT in P. falciparum blood stage parasites leads to anti-
parasitic activity, and reduces parasitemia in an in vivo model of malaria. (a) 
Left: EC50 (inhibitor concentration required for 50% reduction in parasitemia), 
EC50/Ki(app), TC50 (inhibitor concentration required for 50% reduction in YnMyr 
tagging) and EC50/TC50 for 1a-c and 2a-b against P. falciparum. Right: correlation 
between EC50 and TC50 for 1a-c and 2a-b. Ki is also plotted. Horizontal and vertical 
error bars show ± standard error (n  2). (b) Quantification of NMT inhibition in live 
parasites. Schizonts were treated with 1a (0.13-10 µM illustrated by gold shaded 
gradient, or DMSO) followed by tagging with YnMyr (or DMSO). Left: analysis by in-
gel fluorescence following base treatment to remove GPI-anchored proteins. ARF1 
band (marked) was used to calculate TC50 ; Coomassie and Į-BiP are loading 
controls for gel and Western blots, respectively. Right: Analysis by Western blot 
before and after pull-down of YnMyr-tagged; all NMT substrates show dose-
dependent reduction in enrichment, whilst MSP1 (GPI-anchored) does not. Full blots 
in Supplementary Information. (c) Quantification of normalized fluorescence and 
Western blot for ARF1, using GraFit 7.0 (Erithacus Software Ltd, UK). (d) Compound 
2a dosed at 50 mg/kg b.i.d. by intraperitoneal injection (i.p.) (n = 3 animals in 
inhibitor-treated group; n = 2 in control group) reduces parasitemia in the P. berghei 
mouse model of malaria (one-tailed t-test; * p<0.05, ** p<0.01). An error bar is 
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missing in the 3 day control because one animal was euthanized due to severe 
symptoms of malaria. 
Figure 6: NMT inhibition results in loss of the inner membrane complex and 
irreversible loss of parasite viability prior to parasite egress. (a) Top: P. 
falciparum intraerythrocytic life cycle showing approximate timings of life stages; 
parasite egress occurs ~45h post-invasion (PI). Bottom: mean number of nuclei per 
infected red blood cell (iRBC) 45h PI, +/- inhibitor 1a; error bars show ± standard 
deviation from mean (n = 50). (b) Label-free quantification (LFQ) of change in protein 
abundance plotted against significance of change for 1181 proteins in 
pseudoschizonts (NMT inhibition) vs. schizonts (DMSO), 45h PI; see 
Supplementary Table S9 for dataset; groups of proteins are highlighted by function. 
(c) Western blot of parasite proteins 45h PI, cultured in the presence of NMT 
inhibitor (1 µM 1a) or DMSO vehicle, showing depletion of IMC and motor proteins; 
BiP: loading control. (d) Indirect immunofluorescence microscopy of parasites 35h or 
45h PI, cultured in presence of NMT inhibitor (1 µM 1a) or DMSO; green: secondary 
antibody fluorescence; blue: DAPI (nuclear stain); all images at identical 
magnification, white bar = 5 µm. (e) Synchronized parasites were cultured with NMT 
inhibitor (1 µM 1a) or DMSO vehicle to 45 h PI, whereupon medium was exchanged 
for medium containing either NMT inhibitor (1 µM 1a) or DMSO (45h wash-out), and 
parasite life stages analyzed at 55 h PI (p = 0.00081, two-tailed t-test; n = 3). 






